Merck & Co., Inc. - MRK Stock Forecast, Price & News

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 6 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRK shares.
View MRK analyst ratings or view top-rated stocks.

21 Wall Street research analysts have issued 1 year price objectives for Merck & Co., Inc.'s shares. Their MRK share price forecasts range from $98.00 to $135.00. On average, they predict the company's stock price to reach $119.35 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price.
View analysts price targets for MRK or view top-rated stocks among Wall Street analysts.

Merck & Co., Inc.'s stock was trading at $110.95 at the start of the year. Since then, MRK shares have decreased by 5.5% and is now trading at $104.82.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our MRK earnings forecast.

Merck & Co., Inc. will be holding an earnings conference call on Thursday, April 27th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Merck & Co., Inc. (NYSE:MRK) posted its earnings results on Thursday, February, 2nd. The company reported $1.62 EPS for the quarter, topping analysts' consensus estimates of $1.56 by $0.06. The firm had revenue of $13.83 billion for the quarter, compared to analyst estimates of $13.66 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 43.47% and a net margin of 24.49%. The firm's revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.80 earnings per share.
Read the conference call transcript.

Merck & Co., Inc. declared a quarterly dividend on Tuesday, January 24th. Shareholders of record on Wednesday, March 15th will be given a dividend of $0.73 per share on Monday, April 10th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 2.79%. The ex-dividend date is Tuesday, March 14th.
Read our dividend analysis for MRK.

ETFs with the largest weight of Merck & Co., Inc. (NYSE:MRK) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH), VanEck Durable High Dividend ETF (DURA), Invesco Dynamic Pharmaceuticals ETF (PJP), Health Care Select Sector SPDR Fund (XLV), VanEck Pharmaceutical ETF (PPH), iShares U.S. Healthcare ETF (IYH), IQ Healthy Hearts ETF (HART) and Pacer BioThreat Strategy ETF (VIRS).

Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.92 per share and currently has a dividend yield of 2.79%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 51.14%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MRK will have a dividend payout ratio of 33.99% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MRK.

Merck & Co., Inc. updated its FY 2023 earnings guidance on Thursday, February, 2nd. The company provided earnings per share guidance of $6.80-$6.95 for the period, compared to the consensus estimate of $7.36. The company issued revenue guidance of $57.20 billion-$58.70 billion, compared to the consensus revenue estimate of $58.07 billion.

1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.91%), Morgan Stanley (1.65%), Moneta Group Investment Advisors LLC (1.55%), Charles Schwab Investment Management Inc. (1.18%), Price T Rowe Associates Inc. MD (1.04%) and Norges Bank (0.97%). Insiders that own company stock include Caroline Litchfield, Frank Clyburn, Johannes Jacobus Oosthuizen, Joseph Romanelli, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay, Steven Mizell and Wendell P Weeks.
View institutional ownership trends.

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRK stock can currently be purchased for approximately $104.82.

Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $266.10 billion and generates $59.28 billion in revenue each year. The company earns $14.52 billion in net income (profit) each year or $5.71 on an earnings per share basis.

The company employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for the company is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at investor_relations@merck.com, or via fax at 908-735-1253.